Literature DB >> 15542030

The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis.

K Nagahama1, K Aoki, K Nonaka, H Saito, M Takahashi, B J Varghese, H Shimokawa, M Azuma, K Ohya, K Ohyama.   

Abstract

Recently, the involvement of immune responses in metabolic bone disease and/or local bone destruction has received much attention. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a member of the immunoglobulin (Ig) superfamily, negatively regulates T cell activation. The deficiency of CTLA-4 induces profound osteopenia with an increase in osteoclastogenesis, suggesting the important role of activated T cells in osteoclastogenesis. Programmed death-1 (PD-1) is the newly identified immunoregulatory receptor, which also belongs to the Ig superfamily. Both CTLA-4 and PD-1 are induced on activated T cells, however, there are no reports linking PD-1 with osteoclasts. In the present study, we have examined the bone phenotype in PD-1-deficient mice PD-1-/- and the role of PD-1 in osteoclastogenesis and osteoclast function. Both trabecular and cortical bone mineral densities of tibia were significantly increased, as observed in peripheral quantitative computed tomography (pQCT), at 12 weeks of age in PD-1-/- mice. Histomorphometric analysis of the PD-1-/- mice and the age-matched controls at 12 weeks of age showed a 2-fold increase in bone volume (BV/TV) with a 55% decrease in osteoclast number (N.Oc/BS). Bone formation indices were similar in both groups. The number of soluble receptor activator of nuclear factor kappaB ligand (sRANKL)-induced osteoclast-like cells (OCLs) derived from the PD-1-deficient splenocytes was significantly decreased (by 25%). On the other hand, PD-1 deficiency did not affect the bone-resorbing activity of mature osteoclasts. Our results suggest that PD-1 deficiency reduces osteoclastogenesis resulting in an osteopetrotic phenotype. Identical members of the Ig superfamily, CTLA-4 and PD-1, which negatively regulate immune responses, may differentially affect osteoclastogenesis and bone remodeling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542030     DOI: 10.1016/j.bone.2004.06.018

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  13 in total

1.  A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.

Authors:  Kazuhiro Aoki; Hiroaki Saito; Cecile Itzstein; Masaji Ishiguro; Tatsuya Shibata; Roland Blanque; Anower Hussain Mian; Mariko Takahashi; Yoshifumi Suzuki; Masako Yoshimatsu; Akira Yamaguchi; Pierre Deprez; Patrick Mollat; Ramachandran Murali; Keiichi Ohya; William C Horne; Roland Baron
Journal:  J Clin Invest       Date:  2006-05-04       Impact factor: 14.808

2.  Osteomyelitis of the mandible in a patient with osteopetrosis. Case report and review of the literature.

Authors:  Carlos Moreno García; María Asunción Pons García; Raúl González García; Florencio Monje Gil
Journal:  J Maxillofac Oral Surg       Date:  2011-04-20

Review 3.  A Comprehensive Review of Immunoreceptor Regulation of Osteoclasts.

Authors:  Mary Beth Humphrey; Mary C Nakamura
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

4.  When bone becomes marble: Head and neck manifestations of osteopetrosis.

Authors:  Abdul-Latif H Hamdan; Mona M Nabulsi; Firas T Farhat; Rashid K Haidar; Nabil S Fuleihan
Journal:  Paediatr Child Health       Date:  2006-01       Impact factor: 2.253

5.  Lipopolysaccharide-induced bone resorption is increased in TNF type 2 receptor-deficient mice in vivo.

Authors:  Anower Hussain Mian; Hiroaki Saito; Neil Alles; Hitoyata Shimokawa; Kazuhiro Aoki; Keiichi Ohya
Journal:  J Bone Miner Metab       Date:  2008-08-30       Impact factor: 2.626

6.  PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma.

Authors:  Tetsuhiro Kasamatsu; Maaya Awata; Rei Ishihara; Yuki Murakami; Nanami Gotoh; Morio Matsumoto; Morio Sawamura; Akihiko Yokohama; Hiroshi Handa; Norifumi Tsukamoto; Takayuki Saitoh; Hirokazu Murakami
Journal:  Clin Exp Med       Date:  2019-10-16       Impact factor: 3.984

7.  Osteoclast activated FoxP3+ CD8+ T-cells suppress bone resorption in vitro.

Authors:  Zachary S Buchwald; Jennifer R Kiesel; Richard DiPaolo; Meghana S Pagadala; Rajeev Aurora
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

8.  Nanogel-crosslinked nanoparticles increase the inhibitory effects of W9 synthetic peptide on bone loss in a murine bone resorption model.

Authors:  Toshimi Sato; Neil Alles; Masud Khan; Kenichi Nagano; Mariko Takahashi; Yukihiko Tamura; Asako Shimoda; Keiichi Ohya; Kazunari Akiyoshi; Kazuhiro Aoki
Journal:  Int J Nanomedicine       Date:  2015-05-11

9.  Clinical and Radiological Findings of Autosomal Dominant Osteopetrosis Type II: A Case Report.

Authors:  Priyanka Kant; Neelkamal Sharda; Rahul R Bhowate
Journal:  Case Rep Dent       Date:  2013-10-24

10.  PD-1 blockade inhibits osteoclast formation and murine bone cancer pain.

Authors:  Kaiyuan Wang; Yun Gu; Yihan Liao; Sangsu Bang; Christopher R Donnelly; Ouyang Chen; Xueshu Tao; Anthony J Mirando; Matthew J Hilton; Ru-Rong Ji
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.